| Host: |
Goat |
| Applications: |
Pep-ELISA/WB |
| Reactivity: |
Human/Mouse/Rat/Dog/Pig/Cow |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-IKZF1/IKAROS (Internal) is suitable for use in ELISA and Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
WB-0.01-0.03µg/mlELISA-antibody detection limit dilution 1:32000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
IKZF1 |
| Gene ID: |
10320 |
| Uniprot ID: |
IKZF1_HUMAN |
| Immunogen Region: |
Internal |
| Accession Number: |
NP_006051.1; NP_001207694.1; NP_001207695.1; NP_001207696.1; NP_001207697.1; NP_001207698.1; NP_001207699.1; NP_001207700.1 and more |
| Specificity: |
This antibody is expected to recognise all reported human isoforms. |
| Immunogen Sequence: |
DLLRAASENSQDALR |
| Post Translational Modifications | Phosphorylation controls cell-cycle progression from late G(1) stage to S stage. Hyperphosphorylated during G2/M phase. Dephosphorylated state during late G(1) phase. Phosphorylation on Thr-140 is required for DNA and pericentromeric location during mitosis. CK2 is the main kinase, in vitro. GSK3 and CDK may also contribute to phosphorylation of the C-terminal serine and threonine residues. Phosphorylation on these C-terminal residues reduces the DNA-binding ability. Phosphorylation/dephosphorylation events on Ser-13 and Ser-295 regulate TDT expression during thymocyte differentiation. Dephosphorylation by protein phosphatase 1 regulates stability and pericentromeric heterochromatin location. Phosphorylated in both lymphoid and non-lymphoid tissues. Phosphorylation at Ser-361 and Ser-364 downstream of SYK induces nuclear translocation. Sumoylated. Simultaneous sumoylation on the 2 sites results in a loss of both HDAC-dependent and HDAC-independent repression. Has no effect on pericentromeric heterochromatin location. Desumoylated by SENP1. Polyubiquitinated. |
| Function | Transcription regulator of hematopoietic cell differentiation. Binds gamma-satellite DNA. Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta-globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs). Function is isoform-specific and is modulated by dominant-negative inactive isoforms. |
| Protein Name | Dna-Binding Protein IkarosIkaros Family Zinc Finger Protein 1Lymphoid Transcription Factor Lyf-1 |
| Database Links | Reactome: R-HSA-9013508 Q13422-1 |
| Cellular Localisation | NucleusIn Resting LymphocytesDistributed Diffusely Throughout The NucleusLocalizes To Pericentromeric Heterochromatin In Proliferating CellsThis Localization Requires Dna Binding Which Is Regulated By Phosphorylation / Dephosphorylation EventsIsoform Ik2: NucleusIsoform Ik6: Cytoplasm |
| Alternative Antibody Names | Anti-Dna-Binding Protein Ikaros antibodyAnti-Ikaros Family Zinc Finger Protein 1 antibodyAnti-Lymphoid Transcription Factor Lyf-1 antibodyAnti-IKZF1 antibodyAnti-IK1 antibodyAnti-IKAROS antibodyAnti-LYF1 antibodyAnti-ZNFN1A1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
